FDA 483 OBSERVATION · #215 OF 1,945 MOST-CITED

Batch production and Batch Control Record Requirements

FDA cited this observation 141 times across 133 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs141
BY FISCAL YEAR
FY20269
FY202514
FY20249
FY20238
FY202211
FY202112
FY202013
FY201921
FY201812
FY201722
FY201610

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 5.5× the rate of the average FDA-cited firm (42.9% vs 7.8%), across 133 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing and processing.

Mylan Laboratories Limited (FDF-2) · Chhatrapati Sambhajinagar · Drugs · 2026-08-25

The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing.

The Flower Remedy LLC · Englewood, Colorado · Drugs · 2026-06-12

The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing, processing, packing and holding.

GVS TM, Inc · Covina, California · Drugs · 2026-05-01

The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing and processing.

Hyland's Consumer Health Inc. · Los Angeles, California · Drugs · 2026-04-22

The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing.

Gallant Pet Inc · San Diego, California · Drugs · 2026-02-27

The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in processing, packing and holding.

St Mary's Medical Park Pharmacy · Oro Valley, Arizona · Drugs · 2025-12-04

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →